Alpha Teknova, Inc.
Close on Oct 19, 2026
- Market cap
- $364.72M
- P/E (TTM)
- –
- Dividend yield
- –
About Alpha Teknova
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Alpha Teknova, Inc. produces critical reagents used in the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company provides custom and catalog chemical formulations through two primary product categories: Lab Essentials and Clinical Solutions. Its product offerings include pre-poured media plates for cell cultivation, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample processing and purification. Its customers encompass pharmaceutical and biotechnology firms, contract development and manufacturing organizations, in vitro diagnostics entities, and academic and government research institutions.
The company maintains its principal executive offices and manufacturing facilities in Hollister, California. It manufactures both research-use and good manufacturing practice grade materials to supply a customer base of more than 3,000 clients across the life sciences market.
Summary of the business section of Alpha Teknova's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alpha Teknova, Inc.
- Headquarters
- Hollister, CA
- Address
- 2451 Bert Drive 95023
- Phone
- (831) 637-1100
- Employees
- 158, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, San Jose, California
Stock & identifiers
- Ticker
- TKNO
- Exchange
- Nasdaq
- IPO date
- Jun 25, 2021
- Shares outstanding
- 54M, Aug 5, 2026
- Public float
- $53.52M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1850902
- CUSIP
- 02080L102
- ISIN
- US02080L1026
- EIN
- 94-3368109
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stephen Gunstream | President and CEO, Director | 269,497 |
| Matthew Lowell | Chief Financial Officer | 168,376 |
| Damon Terrill | General Counsel and CCO | 41,027 |
| Martha J. Demski | Director | 12,000 |
| Alexander Vos | Director | 102,472 |
| Brett Robertson | Director | 107,472 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 158 employees, all of which were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 2, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 25, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 24, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |